The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
Recruiting now
Conditions studied: Lung Squamous Cell Carcinoma
In brief
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.
Key facts
- Study ID
- NCT05778253
- Run by
- Second Xiangya Hospital of Central South University
- People needed
- 50
- Starts
- 2023-03-23
- Expected to finish
- 2029-09-23
- Last updated by the study team
- 2023-03-21
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histopathology or cytology confirmed the lung squamous cell carcinoma
- Age ranging from 18 to 75
- Agree to participate in this study and sign an informed consent form
- Treatment-naive tumor
- According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor
- Sufficient tissue/blood samples are available to meet research requirements
- The ECOG PS score is 0-1
You may not qualify if…
- Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form
- Non-squamous NSCLC
- Unresectable IIIa-IIIb tumor
- Patients with solid organ or blood system transplantation
- Previous use of CTLA-4, PD-1, or PD-L1 immune checkpoint inhibitors
- Patients with interstitial lung disease
- Patients with acute or chronic infectious disease
- Pregnant and lactating women
- Patients who have undergone other clinical drug trials
Where it is running
- Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China — Changsha, Hunan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.